Detalles de la búsqueda
1.
Impact of CYP2C19 metabolizer status on esophageal mucosal inflammation, acid exposure, and motility among patients on chronic proton-pump inhibitor therapy with refractory symptoms of gastroesophageal reflux disease.
J Can Assoc Gastroenterol
; 7(3): 238-245, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38841142
Resultados
1 -
1
de 1
1
Próxima >
>>